US Pharma MarketingVerastem
Verastem eyes accelerated approval for KRAS G12D drug in 3 cancers; ADC Therapeutics cuts 17% of staff in restructuring. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…
📊 Verastem’s KRAS G12D plans: Verastem’s Tuesday release on its KRAS G12D drug didn’t include much efficacy data — the company said that key update is coming later this year. But, the ...
Source: Endpoints News